Abstract
The aim of this population-based work was to evaluate the impact of having had cancer on COVID-19 risk and prognosis during the first wave of the pandemic (27 February – 13 May 2020) in Reggio Emilia Province. Prevalent cancer cases diagnosed between 1996 and 2020 were linked with the provincial COVID-19 surveillance system. We compared cancer survivors’ cumulative incidence of being tested, testing positive for SARS-CoV-2, and dying of COVID-19 with that of the general population; among COVID-19 patients, we compared cancer survivors’ risk of dying with that of other patients.
During the study period 15,391 people (1,525 cancer survivors - CS) underwent RT-PCR for SARS-CoV-2, of whom 4,541 (449 CS) tested positive; 549 (114 CS) died of COVID-19. The probability of undergoing testing was 29.5% in the general population as well in CS, while the cumulative incidence of being tested, testing positive, and COVID-19 death were lower in CS: age- and sex-adjusted Incidence Rate Ratios were 0.69 [95%CI 0.65-0.73], 0.55 [95%CI 0.50-0.61], and 0.52 [95%CI 0.42-0.64], respectively. Cancer survivors had worse prognosis when diagnosed with COVID-19, particularly those below the age of 70 (odds ratio (OR) of death 4.91 [95%CI 2.38-10.09]), while the OR decreased after age 80 (1.20 [95%CI 0.87-1.65]). The OR was higher for patients with a recent diagnosis (<2 years OR=2.99 [95%CI 1.52-5.89]) or metastases (OR=2.14 [95%CI 0.89-5.16]).
Cancer patients may have adopted behaviors that protected them from infection, but they were still at higher risk of death once infected.
Novelty and impact Cancer survivors during the first wave of the pandemic showed lower COVID-19 cumulative incidence and mortality. When infected, they had worse prognosis, particularly in people younger than age 70, with a recent diagnosis, or with metastases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external fundigs were recivied
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Area Vasta Emilia Nord Ethics Committee on 7 April 2020, protocol n.2020/0045199.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available
List of abbreviations
- CI
- Confidence Interval
- COVID-19
- COronaVIrus Disease 19
- CS
- Cancer Survivors
- ICU
- Intensive Care Unit
- IRR
- Incidence Rate Ratios
- OR
- Odds Ratio
- RE-CR
- Reggio Emilia Cancer Registry
- RT-PCR
- Real Time Polymerase Chain Reaction
- SARS-CoV-2
- Severe Acute Respiratory Syndrome COronaVirus 2
- UK
- United Kingdom
- WHO
- World Health Organization